COMP <GO>
CGEN vs ABBV // REVENUE GROWTH (YOY)
Compugen Ltd. (NASDAQ) VS. AbbVie Inc. (NYSE) • 15-METRIC TALLY: CGEN 8
— ABBV 3
▲ REVENUE GROWTH (YOY) LEADER: CGEN
LAST: $1.98 (-2.94%) • MKT CAP: $193.0M
revenue-growth
161.10%
LAST: $294.89 (+1.41%) • MKT CAP: $513.86B
revenue-growth
8.60%
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (CGEN VS. ABBV)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | CGEN | ABBV | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | 87.30% | 70.20% | +17.10 | CGEN | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | 85.00% | 29.00% | +56.00 | CGEN | /roic <GO> |
| EV/EBITDA & P/E Valuation | 3.2x | 33.3x | -30.10 | CGEN | /valuation <GO> |
| Free Cash Flow Yield | 16.24% | 3.47% | +12.77 | CGEN | /fcf-yield <GO> |
| Operating Margin | 43.10% | 24.60% | +18.50 | CGEN | /operating-margins <GO> |
| Net Profit Margin | 48.60% | 6.90% | +41.70 | CGEN | /net-margins <GO> |
| Revenue Growth (YoY) ACTIVE | 161.10% | 8.60% | +152.50 | CGEN | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 2.27% | -2.27 | ABBV | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | — | 5.33 | — | TIE | /balance-sheet <GO> |
| Piotroski F-Score Quality | 7/9 | 7/9 | 0.00 | TIE | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | — | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 41.1 | 65.1 | -23.96 | ABBV | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | — | 1.15 | — | TIE | /macro-sensitivity <GO> |
| Forward P/E Multiple | 4.6x | 113.1x | -108.50 | CGEN | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $193.0M | $513.86B | -$513.67B | ABBV | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | CGEN REV | ABBV REV | CGEN GROSS % | ABBV GROSS % | CGEN FCF | ABBV FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $72.8M | $61.16B | 87.3% | 70.2% | $31.3M | $17.82B |
| FY 2024 | $27.9M | $56.33B | 71.5% | 70.0% | $49.5M | $17.83B |
| FY 2023 | $33.5M | $54.32B | — | — | -$35.9M | $20.39B |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
CGEN // BETA —
ABBV // BETA 1.15